Characteristics of 190 patients with AML, excluding patients with the M3 subtype, treated according to JALSG protocols
. | . | NPM1 . | . | . | |
|---|---|---|---|---|---|
. | Total N = 190 . | Mutation, n = 49 . | Wild type, n = 141 . | P . | |
| Age, y | 50 (15-85) | 58 (15-77) | 47 (15-85) | .003 | |
| WBC count, × 109/L | 24.5 (0.9-372) | 52.2 (1.0-372) | 23.3 (0.9-337.6) | .002 | |
| PB blast count, × 109/L | 14.9 (0.017-357) | 29.6 (0.093-357) | 12.6 (0.017-324) | .029 | |
| FAB subtype | .004 | ||||
| M0 | 3 | 1 | 2 | ||
| M1 | 44 | 12 | 32 | ||
| M2 | 78 | 10 | 68 | ||
| M4 | 46 | 16 | 30 | ||
| M5 | 14 | 8 | 6 | ||
| M6 | 4 | 1 | 3 | ||
| M7 | 1 | 1 | 0 | ||
| Cytogenetics | <.001 | ||||
| Favorable | 33 | 1 | 32 | ||
| t(8;21) | 27 | 0 | 27 | ||
| inv(16) | 6 | 1 | 5 | ||
| Intermediate | 119 | 42 | 77 | ||
| Normal | 79 | 37 | 42 | ||
| Others | 40 | 5 | 35 | ||
| Poor | 14 | 1 | 13 | ||
| t(9;22) | 3 | 1 | 2 | ||
| del(5) or del(7) | 11 | 0 | 11 | ||
| Unknown | 24 | 5 | 19 | ||
| Outcome | .025 | ||||
| CR | 139 | 42 | 97 | ||
| Failure | 51 | 7 | 44 | ||
| FLT3 | |||||
| Mutation, total | 51 | 31 | 20 | <.001 | |
| ITD mutation | 43 | 27 | 16 | <.001* | |
| D835 mutation | 8 | 4 | 4 | .018* | |
| Wild type | 139 | 18 | 121 | ||
| P53 | NS | ||||
| Mutation | 8 | 1 | 7 | ||
| Wild type | 182 | 48 | 134 | ||
| NRAS | NS | ||||
| Mutation | 26 | 8 | 18 | ||
| Wild type | 164 | 41 | 123 | ||
. | . | NPM1 . | . | . | |
|---|---|---|---|---|---|
. | Total N = 190 . | Mutation, n = 49 . | Wild type, n = 141 . | P . | |
| Age, y | 50 (15-85) | 58 (15-77) | 47 (15-85) | .003 | |
| WBC count, × 109/L | 24.5 (0.9-372) | 52.2 (1.0-372) | 23.3 (0.9-337.6) | .002 | |
| PB blast count, × 109/L | 14.9 (0.017-357) | 29.6 (0.093-357) | 12.6 (0.017-324) | .029 | |
| FAB subtype | .004 | ||||
| M0 | 3 | 1 | 2 | ||
| M1 | 44 | 12 | 32 | ||
| M2 | 78 | 10 | 68 | ||
| M4 | 46 | 16 | 30 | ||
| M5 | 14 | 8 | 6 | ||
| M6 | 4 | 1 | 3 | ||
| M7 | 1 | 1 | 0 | ||
| Cytogenetics | <.001 | ||||
| Favorable | 33 | 1 | 32 | ||
| t(8;21) | 27 | 0 | 27 | ||
| inv(16) | 6 | 1 | 5 | ||
| Intermediate | 119 | 42 | 77 | ||
| Normal | 79 | 37 | 42 | ||
| Others | 40 | 5 | 35 | ||
| Poor | 14 | 1 | 13 | ||
| t(9;22) | 3 | 1 | 2 | ||
| del(5) or del(7) | 11 | 0 | 11 | ||
| Unknown | 24 | 5 | 19 | ||
| Outcome | .025 | ||||
| CR | 139 | 42 | 97 | ||
| Failure | 51 | 7 | 44 | ||
| FLT3 | |||||
| Mutation, total | 51 | 31 | 20 | <.001 | |
| ITD mutation | 43 | 27 | 16 | <.001* | |
| D835 mutation | 8 | 4 | 4 | .018* | |
| Wild type | 139 | 18 | 121 | ||
| P53 | NS | ||||
| Mutation | 8 | 1 | 7 | ||
| Wild type | 182 | 48 | 134 | ||
| NRAS | NS | ||||
| Mutation | 26 | 8 | 18 | ||
| Wild type | 164 | 41 | 123 | ||
Clinical characteristics of the 190 patients with AML, excluding those with the M3 subtype, who were treated according to the JALSG protocols, are shown. Median values (with range in parentheses) are indicated for age, WBC count, and PB blast count. Numbers of patients are shown by FAB type, cytogenetics, outcome, and gene mutation. The favorable risk group was defined by t(8;21) or inv(16); the poor risk group by t(9;22), del(5), or del(7); and the intermediate risk group by normal or other karyotypes.
PB indicates peripheral blood; NS, not significant.
Compared with wild-type variables.